zanidatamab

Home
Ligands
zanidatamab

GtoPdb Ligand ID: 13627

Synonyms: zanidatamab-hrii | Ziihera® | ZW-25 | ZW25

zanidatamab is an approved drug (DA (2024))

Comment: Zanidatamab (ZW25) is an anti-ERBB2 (HER2) monoclonal antibody [3]. It is biparatopic, meaning that it interacts with two independent extracellular epitopes on the ERBB2 receptor. Antibody binding induces ERBB2 internalisation, as well as CDC, ADCC and ADCP. The two epitopes are those bound by trastuzumab (ECD4) and pertuzumab (ECD2). Zanidatamab was designed to treat ERBB2 over-expressing advanced solid tumours, in particular types other than breast cancer [4].

References
1. Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F et al.. (2023) Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol, 24 (7): 772-782. [PMID:37276871]
2. Keam SJ. (2025) Zanidatamab: First Approval. Drugs, [Epub ahead of print]. [PMID:40108069]
3. Weisser NE, Ng GYK, Wickman GR, Dixit SB, Escobar-Cabrera E, Sanches M. (2018) Bispecific antigen-binding constructs targeting HER2. Patent number: US10000576B1. Assignee: Zymeworks Inc Canada. Priority date: 05/01/2018. Publication date: 19/06/2018.
4. (2019) ZW25 Effective in HER2-Positive Cancers. Cancer Discov, 9 (1): 8. [PMID:30504239]

References

1. Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F et al.. (2023)
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Lancet Oncol, 24 (7): 772-782. [PMID:37276871]

2. Keam SJ. (2025)
Zanidatamab: First Approval.
Drugs, [Epub ahead of print]. [PMID:40108069]

3. Weisser NE, Ng GYK, Wickman GR, Dixit SB, Escobar-Cabrera E, Sanches M. (2018)
Bispecific antigen-binding constructs targeting HER2.
Patent number: US10000576B1. Assignee: Zymeworks Inc Canada. Priority date: 05/01/2018. Publication date: 19/06/2018.

4. (2019)
ZW25 Effective in HER2-Positive Cancers.
Cancer Discov, 9 (1): 8. [PMID:30504239]